Xarelto

Xarelto
Fuse809 · Public domain · source
Tradename	Xarelto
Generic	rivaroxaban
Routes	Oral
Class	Anticoagulant; direct factor Xa inhibitor
Legal status	Prescription-only

Xarelto is the trade name for rivaroxaban, an oral anticoagulant developed for prevention and treatment of thromboembolic disorders. It was introduced by a pharmaceutical collaboration and widely adopted for indications including stroke prevention in atrial fibrillation, treatment of deep vein thrombosis, and prophylaxis after orthopedic surgery. The drug displaced many vitamin K antagonist regimens in clinical practice and has been the subject of extensive clinical trials, regulatory review, and litigation.

Medical uses

Rivaroxaban is indicated for prevention and management of thromboembolic events across multiple clinical settings. In nonvalvular Atrial fibrillation it reduces the risk of Ischemic stroke and systemic embolism relative to untreated cohorts and versus historical Warfarin-treated populations. For treatment of acute Deep vein thrombosis and Pulmonary embolism it serves as a single-agent oral option replacing initial parenteral anticoagulation in many protocols. Perioperative prophylaxis following total Hip replacement and total Knee replacement surgery employs rivaroxaban to reduce postoperative venous thromboembolism. Additional uses include secondary prevention after acute venous thromboembolism and prevention of atherothrombotic events in selected patients with chronic Coronary artery disease or Peripheral artery disease.

Pharmacology

Rivaroxaban is a selective, reversible inhibitor of activated coagulation factor Xa, acting within the common pathway of the Coagulation cascade to reduce thrombin generation and thrombus formation. After oral administration it demonstrates high oral bioavailability influenced by dose and fed state, with predictable pharmacokinetics permitting fixed dosing without routine laboratory monitoring. Hepatic metabolism involves cytochrome P450 isoforms including CYP3A4 and CYP2J2 and non‑CYP pathways, with significant renal elimination of unchanged drug and metabolites. Protein binding in plasma is high, affecting distribution and dialysis removal. The pharmacodynamic effect is measured indirectly via anti‑factor Xa assays rather than routine Prothrombin time for clinical management.

Dosage and administration

Dosing varies by indication, renal function, and concomitant medications. Common regimens include once-daily dosing for stroke prevention in nonvalvular Atrial fibrillation and for prevention after orthopedic surgery, and initial twice-daily dosing for treatment of acute venous thromboembolism followed by once-daily maintenance. Dose adjustments are recommended for patients with impaired renal function, with thresholds referenced to estimated Glomerular filtration rate or creatinine clearance. Administration with food enhances absorption at higher doses; instructions for fasting versus fed dosing differ by approved indication. Switching to or from other anticoagulants, including Heparin, low molecular weight Enoxaparin, and vitamin K antagonists, requires protocolized transition strategies to avoid periods of under- or over-anticoagulation.

Adverse effects and contraindications

The predominant serious adverse effect is bleeding, ranging from minor hemorrhage to life‑threatening intracranial or gastrointestinal bleeding. Risk factors for hemorrhage include advanced age, concurrent use of antiplatelet agents such as Aspirin or Clopidogrel, renal impairment, and prior bleeding history. Other reported adverse events include hepatic enzyme elevations and hypersensitivity reactions. Absolute contraindications include active clinically significant bleeding and severe hypersensitivity to the compound. Caution is advised in patients with prosthetic heart valves, severe hepatic impairment associated with coagulopathy, and concomitant medications that markedly alter rivaroxaban plasma levels.

Drug interactions

Rivaroxaban is susceptible to pharmacokinetic interactions mediated by strong inhibitors or inducers of CYP3A4 and P-glycoprotein. Concomitant use with potent combined CYP3A4 and P‑glycoprotein inhibitors such as certain azole antifungals or protease inhibitors can increase bleeding risk by elevating exposure. Conversely, strong enzyme inducers including some Rifampin-class antimicrobials, Phenytoin, and Carbamazepine may reduce efficacy by lowering plasma concentrations. Co-administration with antiplatelet agents, nonsteroidal anti-inflammatory drugs like Ibuprofen, or thrombolytic therapies increases hemorrhagic risk. Clinical decisions require review of interacting agents from formularies, specialty guidelines, and consultation with pharmacists experienced in anticoagulant management.

Clinical trials and efficacy

Pivotal randomized controlled trials compared rivaroxaban with standard care across indications. In atrial fibrillation, trials demonstrated noninferiority to warfarin for prevention of stroke and systemic embolism with differences in bleeding profiles. Venous thromboembolism treatment trials showed similar efficacy to enoxaparin followed by warfarin with simplified oral administration. Orthopedic prophylaxis studies reported lower venous thromboembolism rates versus enoxaparin regimens in selected populations. Postmarketing studies and real‑world evidence have extended findings to diverse healthcare settings, while meta-analyses have characterized comparative risks for major bleeding, intracranial hemorrhage, and gastrointestinal bleeding relative to vitamin K antagonists and other direct oral anticoagulants.

Regulatory status and litigation

Rivaroxaban received regulatory approvals from agencies including the Food and Drug Administration, the European Medicines Agency, and national authorities across multiple jurisdictions for specified indications. Market authorization timelines varied by indication and region, reflecting review of efficacy and safety datasets. The product and its manufacturers have been involved in litigation concerning labeling, adverse event reporting, and restitution claims; class action and mass tort actions in several court systems addressed allegations related to bleeding risks and purported inadequate warnings. Settlements and court decisions influenced labeling updates, risk management strategies, and postmarketing surveillance commitments overseen by regulatory bodies and judicial processes.

Category:Anticoagulants